Tolerability of re-vaccination
Of the 214 patients showing any symptom in line with a possible allergic reaction after the first vaccination, 71 patients did not show any immediate allergic symptoms after re-vaccination with the identical (n=57) or a non-identical SARS-CoV-2 vaccine (n=13) and for one patient the type of the second vaccine is unknown. Six further patients showed similar tolerability to re-vaccination and one patient had urticarial after the re-vaccination. In some of the above mentioned cases, the second dose was given fractionated (n=9), in other cases, the vaccination was given as a whole dose with extended emergency preparedness and some patients received premedication before vaccination (n=3) (antihistamines and oral corticosteroids).
Finally, two cases were identified for which the vaccination with the approved SARS-CoV-2 vaccinations is contraindicated. Five patients denied revaccination, one patient denied completely the vaccination and one patient died (due to other medical reasons) and could not be revaccinated. For one patient the re-vaccination was not applicable, due to previous COVID-19 Infection.
The allergy workup revealed from a total of 334 patients in 57 cases (17%) a suspicion of type 1 sensitization against the SARS-CoV-vaccine and/or the excipients defined as one positive skin test and/or basophil activation test. A re-vaccination with any available SARS-CoV-2 vaccine of patients from this group was contraindicated in one case only, due to SPT positivity to several vaccines. 27/57 patients were successfully re-vaccinated (26 with the identical vaccine). Three patients denied completely the vaccination, in one patient of these the re-vaccination was not necessary, due to previous COVID-19 infection and one patient died (due to other medical reasons).